News -
A new approach to treating CNS disorders
Through neural plasticity, our brain continuously develops new neural connections as a response to the environment. Understanding the potential of neural plasticity in clinical settings may help unlock new patterns for treatment of central nervous system disorders, including MDD.
Our story
Taking on major depressive disorder (MDD)
MDD affects over 18 million adults in the United States every year. While the antidepressant market continues to grow and expand, nearly two-thirds of patients do not meaningfully improve with current options. Given this significant need, our innovative research aims to provide safe, efficacious, and rapid-acting treatment options.
Our focus
New options for tomorrow
REL-1017 has entered phase 3 development for the treatment of MDD. REL-1017 has the potential to be a once-daily, oral pill that blocks hyperactive NMDA receptor (NMDAR) channels associated with MDD, while maintaining the physiological activity of glutamate, the major excitatory neurotransmitter in the brain.
Our portfolio
